The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Apremilast for patients with genital psoriasis: Week 32 results from the phase III DISCREET trial
|
The multicenter, randomized, double-blind, placebo-controlled phase III DISCREET trial (NCT03777436) evaluated the safety and efficacy of apremilast, an oral PDE4 inhibitor, in patients with moderate-to-severe genital psoriasis.1 Patients were randomized 1:1 to receive either apremilast 30 mg twice daily (n = 143) or placebo (n = 146) for 16 weeks.1 At Week 16, all patients (n = 229) entered the apremilast extension phase and received apremilast up to Week 32.1 Week 16 results were previously reported by the PsOPsA Hub. Week 32 results were presented at the EADV 2024 Congress by Joseph Merola.1 |
| Key learnings |
| At Week 32, the modified genital PGA response rates were 40.3% and 51.8% and the overall sPGA rates were 30.3% and 33.6% in patients who received apremilast and placebo/apremilast, respectively. |
| GPI-NRS response rates were 46.5% and 48.4% in patients who received apremilast and placebo/apremilast, respectively. |
| DLQI improved from baseline by −48.6% and −55.9% and DLQI-Q9, focused on sexual function, improved by −58.8% and −57.2% in patients who received apremilast and placebo/apremilast, respectively. |
| The safety outcomes were consistent with the known safety profile of apremilast and similar to the Week 16 analysis. |
| Patients with moderate-to-severe genital psoriasis treated with apremilast had a clinically meaningful reduction in disease severity, signs, and symptoms, and improved quality of life, regardless of apremilast or placebo treatment in the first 16 weeks. |
Abbreviations: DLQI, Dermatology Life Quality Index; DLQI-Q9, DLQI question 9; EADV, European Academy of Dermatology and Venereology; GPI-NRS, Genital Psoriasis Itch Numeric Rating Scale; PDE4, phosphodiesterase 4; PGA, Physician’s Global Assessment; QoL, quality of life; sPGA, static PGA.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
